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Abstract
Background: NRG1 gene fusions may be clinically actionable, since cancers carrying the fusion transcripts can be
sensitive to tyrosine kinase inhibitors. The NRG1 gene encodes ligands for the HER2(ERBB2)-ERBB3 heterodimeric
receptor tyrosine kinase, and the gene fusions are thought to lead to autocrine stimulation of the receptor. The
NRG1 fusion expressed in the breast cancer cell line MDA-MB-175 serves as a model example of such fusions,
showing the proposed autocrine loop and exceptional drug sensitivity. However, its structure has not been properly
characterised, its oncogenic activity has not been fully explained, and there is limited data on such fusions in breast
cancer.
Methods: We analysed genomic rearrangements and transcripts of NRG1 in MDA-MB-175 and a panel of 571 breast
cancers.
Results: We found that the MDA-MB-175 fusion—originally reported as a DOC4(TENM4)-NRG1 fusion, lacking the
cytoplasmic tail of NRG1—is in reality a double fusion, PPP6R3-TENM4-NRG1, producing multiple transcripts, some of
which include the cytoplasmic tail. We hypothesise that many NRG1 fusions may be oncogenic not for lacking the
cytoplasmic domain but because they do not encode NRG1’s nuclear-localised form. The fusion in MDA-MB-175 is
the result of a very complex genomic rearrangement, which we partially characterised, that creates additional
expressed gene fusions, RSF1-TENM4, TPCN2-RSF1, and MRPL48-GAB2.
We searched for NRG1 rearrangements in 571 breast cancers subjected to genome sequencing and transcriptome
sequencing and found four cases (0.7%) with fusions, WRN-NRG1, FAM91A1-NRG1, ARHGEF39-NRG1, and ZNF704-
NRG1, all splicing into NRG1 at the same exon as in MDA-MB-175. However, the WRN-NRG1 and ARHGEF39-NRG1
fusions were out of frame. We identified rearrangements of NRG1 in many more (8% of) cases that seemed more
likely to inactivate than to create activating fusions, or whose outcome could not be predicted because they were
complex, or both. This is not surprising because NRG1 can be pro-apoptotic and is inactivated in some breast
cancers.
Conclusions: Our results highlight the complexity of rearrangements of NRG1 in breast cancers and confirm that
some do not activate but inactivate. Careful interpretation of NRG1 rearrangements will therefore be necessary for
appropriate patient management.
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Introduction
The NRG1 gene encodes ligands for the ERBB2(HER2)-
ERBB3 heterodimeric receptor tyrosine kinase [1–3].
Gene fusions of NRG1 such as CD74-NRG1 and
SLC33A2-NRG1 have been found at low frequency in a
wide range of carcinomas including lung, breast, colo-
rectal, ovarian, and pancreatic cancers and with a wide
range of fusion partners ([4–9], reviewed in [10]). Al-
though the frequency is generally low, 0.2% overall in a
wide range of carcinomas according to Jonna et al. [9], it
rises to roughly 25% in the rare invasive mucinous
adenocarcinoma of the lung [6].
The fusions that retain the EGF-like receptor-binding
domain are thought to be activating and oncogenic by
creating an autocrine loop in which the fused NRG1
protein stimulates the heterodimeric ERBB2-ERBB3 re-
ceptor [3, 7, 11, 12]. Such cancers might be very sensi-
tive to inhibition of ERBB2-ERBB3 [13], and there are
several recent reports of good responses in patients to
anti-ERBB2 or anti-ERBB3 therapy, including anti-
ERBB3 antibody and HER-family kinase inhibitors such
as the pan-ERBB inhibitor afatinib. This has led to the
proposal that NRG1 fusions are clinically actionable [7,
8, 14–18] and, as a result, NRG1 fusions have been in-
cluded in the TAPUR study matching patients that have
driver mutations to appropriate therapy (Clinical trials
ref. NCT02693535).
The NRG1 fusion of the breast cancer cell line
MDA-MB-175 [11, 19, 20] was the first NRG1 fusion
reported and serves as a model of such fusions and
the proposed autocrine loop. MDA-MB-175 cells se-
crete a fused NRG1 protein that was originally
thought to be an isoform of NRG1 [11] but subse-
quently was reported to be a DOC4 (now renamed
TENM4)-NRG1 fusion [19, 20]. The cells secrete a
fusion protein that stimulates ERBB3 phosphorylation
when added to other cells [13], and they are very sen-
sitive to tyrosine kinase inhibitors, being the cancer
cell line most sensitive to a dual ERBB2-ERBB3 in-
hibitor in the survey of Wilson et al. [13].
However, the structure of this NRG1 fusion has not
been completely described. It was reported to be a
DOC4/TENM4-NRG1 fusion, but the original cDNA se-
quence [11] is in fact a double fusion PPP6R3-TENM4-
NRG1 implying a complex genomic rearrangement. Fur-
thermore, normal NRG1 has many splice variants: the
original fusion cDNA—and indeed many of the fusion
transcripts described in clinical samples—represents only
one of potentially many isoforms. In particular, the ori-
ginal cDNA lacked the cytoplasmic tail, and this has
been hypothesised to enhance its oncogenic activity,
since the cytoplasmic tail has been linked to pro-
apoptotic activity of NRG1 [21] (see also the “Discussion”
section).
We report here the full transcript structure with alter-
natively spliced variants, partial characterisation of the
underlying complex genomic rearrangement, and other
gene fusions from the same genomic regions that pre-
sumably result from the same complex rearrangement.
We also report a search for NRG1 fusions and rear-
rangements in nearly 600 breast cancers.
Methods
MDA-MB-175 (ATCC catalogue HTB-25) was obtained
from the collection of Dr. M. J. O’Hare, Ludwig Cancer
Research (who also provided the immortalised normal
breast cell line HB4A [22]), and is the same stock as we
used for karyotyping [23]. Its authenticity is confirmed
by the presence of the fusion. It was maintained in
DMEM Glutamax +15% FBS.
Genome positions are given relative to hg19/GRCh37
unless otherwise marked.
Paired-end transcriptome sequencing (RNA-seq) for
MDA-MB-175 used Illumina’s stranded RNA kit with
polyA selection. Forty-one million mapped reads were
obtained after removing duplicates and were analysed
with TopHat-Fusion [24]. Additional cell line transcrip-
tome (RNA-seq) data was downloaded from the Cancer
Genome Atlas (TCGA) project, using the Cancer Gen-
omics Hub (now superseded by www.cancer.gov) as
mapped sequence reads.
Genomic DNA sequencing of MDA-MB-175: DNA
was captured by hybridisation using Nextera Custom
Target Enrichment kit (Illumina, Great Chesterford,
UK). Nextera uses a modified Tn5 transposase to
simultaneously fragment DNA and attach a trans-
poson sequence to both ends of the fragments. Frag-
ments were PCR amplified and barcoded in 11 cycles
of PCR; quantified using Qubit HS dsDNA assay (Life
Technologies, CA.) and 500 ng pooled into a pool of
twelve samples. 80-mer enrichment probes were de-
signed by Illumina to NRG1 genomic regions, from
hg19/chr8:31696790-31873798 and 32140458-
32310458, both within intron 1, at intermediate probe
density, and 32320000-32500000, at dense probe
density, 85 kb upstream of exon 2 to just beyond
exon 6. Capture was performed twice to increase spe-
cificity. Enriched libraries were amplified using uni-
versal primers in 11 cycles of PCR, their quality
assessed using Bioanalyser (Agilent Technologies, Ca.)
and quantified using KAPA Library Quantification
Kits (Kapa Biosystems, Ma.). Four capture reactions
(48 samples) were pooled for 125-bp paired-end se-
quencing in a lane of Illumina HiSeq 2000. Structural
variants were called as described [25] and calls manu-
ally inspected using the IGV (Integrative Genomics
Viewer). Copy number was estimated from read
counts using geneCN [26, 27].
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Breast cancers
Data was from consecutive consented patients with a
successful DNA extraction, in the Cambridge Perso-
nalised Breast Cancer Program, led by JEA and CC,
to be described elsewhere. Eighty-eight percent tu-
mours were primary, 12% metastatic at sampling
(Supplementary Tables 3 and 4 give details). DNA
and RNA from tumours and DNA from matched
blood were paired-end sequenced by Illumina, Great
Chesterford, UK, using respectively the TruSeq® DNA
PCR-Free Library Preparation kit or the TruSeq®
Stranded Total RNA Library Preparation Gold kit.
For DNA, reads were 150 bp to minimum 75X, typic-
ally 100X, coverage of tumour after alignment and re-
moval of duplicates; for matched normal minimum
30X, typically near 40X. RNA sequencing was ap-
proximately 100 million 75-bp read pairs per tumour,
but without removal of duplicates. Structural variants
and copy number aberrations were called by Illumina
using Manta [28] following alignment with Isaac [29]
to GRCh38 with decoy sequences. Structural variants
were further filtered to remove calls with any sup-
porting reads in the matched normal, calls also found
in the pooled matched blood normal samples, and
calls involving unassembled or mitochondrial chromo-
somes [25].
Fusion transcripts were identified in individual RNA
reads by text searching the original sequence (fastq)
files for NRG1 splice acceptor and splice donor se-
quences and extracting adjacent sequences. DNA
structural variant calls were available for 250 patients
of which 235 had RNA sequencing; RNA sequences
from a further 336 cases were searched for additional
fusions and, in the two cases identified, the matching
DNA sequences were analysed individually for
rearrangements.
Results
The NRG1 fusion in MDA-MB-175 is a double fusion
PPP6R3-TENM4-NRG1
The NRG1 fusion transcript of breast cancer cell line
MDA-MB-175 was originally described as a fusion of
DOC4 (now TENM4, encoding teneurin transmembrane
protein 4, also called ODZ4) to NRG1 [11, 19, 20]. How-
ever, the original cDNA sequence Genbank AF009227
[11] is in fact a double fusion, 5′ PPP6R3-TENM4-NRG1
3′ (Supplementary Table 1; Fig. 1). The fusion cDNA
comprises the first, non-coding exon of PPP6R3 (protein
phosphatase 6, regulatory subunit 3; formerly SAPS3),
correctly spliced to exons 3 to 12 of TENM4, and then
to exon 3 of NRG1 (exons numbered according to their
order in the genome, exon 3 is the second exon of many
normal NRG1 transcripts; Fig. 1, Supplementary Table 2).
The PPP6R3-TENM4 (formerly SAPS3-ODZ4) cDNA
junction was previously detected by Robinson et al.
(Supplementary data of ref. [30]) in transcriptome se-
quencing, but recorded as a separate fusion.
We confirmed the double-fusion structure, first by
RT-PCR and Sanger sequencing (Fig. 1 c, d) and paired-
end sequencing of cDNA fragments (‘RNA-seq’) (Sup-
plementary Figure 1) and finally by amplifying, cloning,
and Sanger sequencing complete cDNAs extending from
exon 1 of PPP6R3 through the TENM4 component to
various exons of NRG1 (Fig. 1; Supplementary
Textfile 1).
The fusion extends to the 3′ end of NRG1, including the
cytoplasmic tail
NRG1 has many alternative isoforms [1]. Although the
original cDNA, AF009227 [11], lacks the cytoplasmic
exons 12 to 18, terminating in exon 11ext (Fig. 1; Sup-
plementary Tables 1, 2), which defines normal β3 iso-
forms such as Heregulin-β3 (RefSeq NM_013958) and
NRG1 Type III-β3, we detected expression in MDA-MB-
175 of all the later exons as well, in fusion transcripts
(Fig. 1). We amplified complete cDNAs extending from
PPP6R3 exon 1 to the last NRG1 exon, exon 18, which
on cloning included at least three isoforms: we detected
both the alpha and beta forms of NRG1 (respectively in-
cluding NRG1 exon 10 or 11), and two transcripts in-
cluded an additional, unannotated exon we designated
‘exon int15’. This exon is in reverse orientation within
intron 15 of TENM4, at hg19/chr11:78,506,385-78,506,
462 (hg38 chr11:78795340-78795417), and therefore
must be transcribed from an inverted fragment of
chromosome 11 inserted into the main TENM4-NRG1
junction (Fig. 1; Supplementary Table 2; Supplementary
Textfile 1). RNAseq confirmed the presence of this exon
(Supplementary Figure 2 panel C), but showed it was a
minor variant, as only 24% (38/160) of split reads across
the junction with NRG1 exon 3 were from this exon (the
others were all from TENM4 exon 12). This exon would
insert 26 amino acids and preserve the reading frame
downstream.
We also amplified the originally reported transcript
that terminates in an extension of exon 11 and a variant
that included the inverted exon int15 (Fig. 1; Supple-
mentary Textfile 1).
Other gene fusion transcripts: RSF1-TENM4, TPCN2-RSF1,
MRPL48-GAB2
RNAseq revealed other cDNA junctions in MDA-MB-
175 from further gene fusions caused by related rear-
rangements within chromosome 11, and we confirmed
them by RT-PCR: RSF1 exon 3 fused to exon 15 of
TENM4, TPCN2 exon 5 fused to RSF1 exon 4, and
MRPL48 exon 3 fused to GAB2 exon 2 (Supplementary
Figures 3, 4). A normal transcript of RSF1, exons 1 to 5,
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was also detected by PCR, and RNAseq showed expres-
sion of all RSF1 exons with normal splicing, the appar-
ently normal expression exceeding that of the fusions.
Expression of NRG1, TENM4, and PPP6R3 other than in the
fusion
NRG1, TENM4, and PPP6R3 are all expressed in normal
breast, PPP6R3 strongly, NRG1 and TENM4 weakly
(GTEx RNAseq database accessed via UCSC Genome
browser and [31]). We asked whether there was expres-
sion of unrearranged NRG1, TENM4, and PPP6R3 in
MDA-MB-175 or of a hypothetical precursor fusion,
PPP6R3-TENM4 or TENM4-NRG1, a copy of which
might still be present. For NRG1, no expression was de-
tected from the major transcription start sites of NRG1
exon1, exon 2, and exon 7, either by RT-PCR or tran-
scriptome sequencing (RNA-seq; (Supplementary Figure
2)), and all splicing into NRG1 exon 3 was from TENM4
exons 12 or int15 (total 160 split reads). NRG1 exon 2 is
the main transcription start site in normal breast epithe-
lial cells and carcinoma cell lines [31]. We previously
showed that in MDA-MB-175, the CpG island at exon 2
is methylated [31]. However, a recently described alter-
native minor transcription start site, exon 8, found in
isoform ndf43c/VI-1 (Refseq NM_001159996 and NM_
001322197) was weakly expressed (Supplementary
Fig. 2 Partial genomic structure of rearrangements in MDA-MB-175 from capture sequencing and RNA fusions. Regions capture-sequenced
shown as grey shading: lighter grey, 32.14–32.310 Mb, intermediate probe density; darker grey, 32.320–32.5 Mb, denser probes. All positions hg19.
Solid arcs, breakpoint joins from capture sequencing, with positions of breakpoints given in bp, with direction of join and a one-letter junction
identifier, e.g. on chr8, junction marked ‘32,236,901 - F’, is junction F at 32,236,901 bp, ‘-’ indicating that sequence to the right of junction is
retained. Dotted arcs, possible junctions in unsequenced regions, deduced from observed gene fusion transcripts. Blue, genes with their locations
in Mb and +ve or −ve strand; numbered exons shown above line for + strand genes, below for − strand genes. Red, exons in fusion transcripts;
red arrows, direction of transcription of fusion. Junctions on chromosome 8 correspond to the major copy number steps shown by the capture
sequencing of this region of chromosome 8 (Supplementary Figure 6)
(See figure on previous page.)
Fig. 1 Structure of PPP6R3-TENM4-NRG1 fusion transcripts expressed by MDA-MB-175. a Schematic of genes involved, showing hypothetical
genomic structure deduced from the transcripts. Exons from PPP6R3 are shown in blue, TENM4 exons, red, NRG1 exons, green, with the
transmembrane domain exon in black. Cryptic exon from TENM4 intron 15 in reverse orientation, orange. In grey, possible position of exon 16 of
TENM4 for orientation, not present in fusion transcripts. NRG1 exons are numbered according to genome position. Exon 9 is the receptor-binding
domain; exons 3 and 4 are the Ig-like domain. Exons 1, 2, 7, and 8 are omitted because they are normal transcription start sites and do not
participate in the fusion. Where transcription terminates in exon 11, the exon is extended to give the β3 isoforms. Genomic positions are hg19. b
Transcripts detected. In colour, transcripts amplified by PCR and cloned; grey, additional isoform that includes exon 17, inferred from successful
amplification between primers shown. Asterisk marks transcript matching original cDNA of Schaefer et al. [11]. c Examples of confirmation of
junctions by PCR, showing inclusion of cytoplasmic exons of NRG1 in fusion. Primer pairs are shown by arrows in a. HB4a is control normal breast
cell line. d Sequences through junctions
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Figures 1 and 2), and we amplified a cDNA extending
from exon 8 to exon 18, comprising exons 8 to 10 and
13 to 18, and a second cDNA with exon 17 omitted. We
presume these are normal transcripts, since splicing into
exon 8 has not been described, and PCR failed to amp-
lify between TENM4 and exon 8 of NRG1.
Similarly, almost no expression was detected from
TENM4 exons 1 and 2 (Supplementary Figures 1 and 2;
manual search found 5 split reads joining exons 1 and
2), although data from the Cancer Genome Atlas
(TCGA) shows that these are expressed in other breast
cancer cell lines such as MCF7 and MDA-MB-134, and
we failed to amplify cDNA joining exon 2 of TENM4 to
NRG1. By RNAseq, only 1 of 145 split reads that in-
cluded the splice acceptor of TENM4 exon 3 matched
exon 2 splice donor; all others were consistent with spli-
cing in from PPP6R3 (two included an alternative exon
2 of PPP6R3 and two reads included intronic sequence
from upstream of exon 3 in TENM4). This seems to rule
out significant expression of both normal TENM4 and a
TENM4-NRG1 precursor. However, there was good ex-
pression of TENM4 exons beyond the last exon involved
in the fusion, exon 12, and splicing was normal, includ-
ing exon 12–exon 13. Although some of this expression
would be the RSF1-TENM4 fusion (Supplementary Fig-
ures 1 and 2), this only starts at TENM4 exon 15 and
there is splicing exon14 to exon 15, and no other spli-
cing anomalies were detected: a PPP6R3-TENM4 fusion
may therefore remain. We failed to amplify between
PPP6R3 exon 1 and TENM4 exon 16, but this might
have been technical failure.
Expression of PPP6R3 exons not in the fusion was also
evident, presumably from a normal copy (Supplementary
Figure 1).
Genome rearrangements associated with the fusions
We were able to demonstrate some of the complexity of
the underlying genomic rearrangements that formed the
PPP6R3-TENM4-NRG1 fusion, by constructing a plaus-
ible, though incomplete, model of them from the gene
fusions, data from FISH (fluorescence in situ hybridisa-
tion), paired-end sequencing of part of the NRG1 region,
and copy number.
The fusion cDNA suggests that it was formed by a
large inversion of chromosome 11 that joined PPP6R3 to
TENM4 and a translocation joining chromosome 11 to
chromosome 8 upstream of exon 3 of NRG1, with an
additional local inversion that allows exon int15 to be
included in some transcripts (Fig. 2).
Cytogenetically, a typical metaphase of MDA-MB-175
has two copies of an unbalanced 8;11 translocation, plus
apparently normal chromosomes 8 (three copies) and 11
(two copies) [19, 23]. FISH with BAC clones showed
that, as expected, the 8;11 translocation chromosome
harbours all the three major genomic segments that
form the fusion, apparently in more than one copy, with
the PPP6R3, TENM4, and NRG1 regions colocalised,
while the normal chromosomes retain single copies
(Supplementary Figure 5).
We identified a number of rearrangement junctions in
genomic DNA that are consistent with the fusions, by
paired-end sequencing of DNA captured by hybridisa-
tion from around exons 2 to 6 of NRG1 (hg19/chr8: 31.7
to 31.874 and 32.14 to 32.50Mb). This identified junc-
tions within chromosome 8 and between this region and
chromosome 11 (Fig. 2). These were curated manually
using the Integrative Genomics Viewer (IGV), revealing
an additional small inversion on chromosome 11 appar-
ently encompassing the 8-11 junction that forms the fu-
sion. Genomic copy number analysis by counting reads
from the capture-sequencing (Supplementary Figure 6)
confirmed the presence of unbalanced junctions corre-
sponding to the rearrangement junctions in the region
captured: up at junction marked F in Fig. 2, down at
junction D, and up at the cluster of breakpoints marked
A1, A2, B, C, and E.
The rearrangements shown are only part of a more
complex picture. Array-CGH (array-comparative gen-
omic hybridization) from [32] suggests multiple copy
number steps in the rearranged regions (Supplementary
Figure 6), and the additional fusions found suggest add-
itional rearrangements, shown as dotted lines in Fig. 2.
Our capture sequencing would not have found junctions
that did not include the captured NRG1 region—notably
the TENM4-RSF1 and PPP6R3-TENM4 junctions.
Overexpression of the fusion
We transfected, into HEK293 cells, FLAG-tagged coding
sequences of the principal isoforms of the fusion, with
and without the cytoplasmic tail. FLAG-tagged protein
of the expected size was detected on harvesting cells at
48 h (Supplementary Figure 7), showing that such iso-
forms can be expressed at least transiently. We also
transfected isoforms that included the extra inverted
exon int15, but these were not detectably expressed.
NRG1 fusions in primary breast cancers
To put the MDA-MB-175 fusion in the context of breast
cancer, we surveyed 571 consecutive consented cases of
breast cancer subjected to both whole-genome DNA and
RNA sequencing. We identified four NRG1 fusions of
the form (geneA)-NRG1, that were both predicted from
DNA rearrangement junctions and found in RNA se-
quence reads: WRN-NRG1, FAM91A1-NRG1, ARHG
EF39-NRG1, and ZNF704-NRG1 (Supplementary Table 3,
which also gives tumour subtypes and other known
driver mutations). However, while the FAM91A1-NRG1
fusion was in frame, the WRN-NRG1 and ARHGEF39-
Howarth et al. Breast Cancer Research            (2021) 23:3 Page 6 of 12
NRG1 fusions were not. The ZNF704-NRG1 fusion was
to an undocumented exon in ZNF704, so its reading
frame is unknown, but the fused sequence was in frame
with NRG1.
All four fusions spliced into NRG1 at exon 3, as in
MDA-MB175, and many of the fusions described by
others; no fusions that spliced into exons 4 to 9 (the
receptor-binding exon) were detected. All were created
by internal rearrangement of chromosome 8 (Supple-
mentary Table 3). A WRN-NRG1 fusion has been de-
scribed before—WRN is the gene immediately 5′ to
NRG1 so the fusion is typically formed by genomic dele-
tion—but the previous example included no WRN cod-
ing sequence, so would presumably have resulted in
expression of NRG1 protein [5, 9]. A fusion of ZNF704
has also been reported, but to MYC, in the lung [5].
Detecting these fusions was not straightforward. They
were not called from the RNA sequences by the fusion
detection software STAR-fusion [33], because of insuffi-
cient read coverage—indeed, in two of four cases, our
RNA sequencing yielded only one or two split fusion
reads (Supplementary Table 3). In addition, the ZNF704-
NRG1 fusion spliced from an undocumented exon so
would not have been found using software that only
considered known exons. The prediction of the ZNF704-
NRG1 fusion was tentative because the genomic re-
arrangement is complex. A plausible reconstruction
(Supplementary Figure 8) was that in addition to the
ZNF704-NRG1 junction, there was a tandem duplication
of about 57 kb of NRG1, encompassing the unused exon
7, with insertion of 24 kb of inverted sequence into the
duplication junction.
A further 20 of the first 250 breast cancer cases had
breakpoints within NRG1 by DNA sequencing, 13 of
which had multiple breakpoints, which would make fu-
sion prediction difficult (Supplementary Table 4). No fu-
sion transcripts were detected in the matching RNA
sequencing, but depth of sequencing might have been
limiting.
The short-read RNA sequencing did not enable us to
determine whether these fusions included the cytoplas-
mic tail exons. Expression of these exons was detected
(Supplementary Table 3)—clearly in two cases,
FAM91A1-NRG1 and ARHGEF39-NRG1 but not conclu-
sively in the other two cases where there were too few
reads overall—but we could not tell whether these reads
were from fusion transcripts or normal transcripts, from
tumour or normal cells.
Discussion
We have shown that the NRG1 fusion of MDA-MB-175
is more complex than previously described, being a
double fusion PPP6R3-TENM4-NRG1 with multiple al-
ternative transcripts, some including the cytoplasmic tail,
and it is the result of complex genomic rearrangements.
We also confirmed that similar fusions—coding se-
quence of another gene splicing into genomic exon 3 of
NRG1—are found in breast cancers, supporting the use
of this fusion as a model example. The structure of these
fusions has implications for clinical identification of
NRG1 fusions, for understanding the subcellular location
and secretion of NRG1 fusion proteins, and explanations
of their oncogenicity.
Identifying NRG1 fusions is challenging
Our search for NRG1 fusions in breast cases, and the
complexity of the fusion in MDA-MB-175, illustrate that
identifying NRG1 fusions in clinical cases is not straight-
forward. We needed both the DNA and RNA sequen-
cing to detect the fusions in cancers: there were too few
supporting reads in the RNA sequencing to call them
from RNA alone, while prediction from the DNA rear-
rangements alone would only have been provisional, par-
ticularly in our 14 examples where there were multiple
breaks in NRG1. MDA-MB-175 itself is a case in point:
with 7 breakpoints called within NRG1 (Fig. 2), predic-
tion of a fusion would have been very difficult and un-
certain. Although we found 4 examples in 571 cases
(0.7%), in rough agreement with the 2/120 found by Kim
et al. [34] but a substantially higher prevalence than
others [8, 9], there might well have been more.
The importance of correct interpretation is underlined
by the probability that some NRG1 rearrangements—in-
cluding presumably the out-of-frame fusions—are inacti-
vating events as discussed below. Probably our [35] and
others’ [36] estimates of around 5% of breast cancers
having breaks within NRG1 by FISH includes many
cases where there is no fusion. In conclusion (as noted
before [6, 8–10]), RNA analysis is probably necessary,
and combining with DNA sequencing improves sensitiv-
ity and specificity, but, even with both, sensitive identifi-
cation of fusions is challenging.
Structure of the MDA-MB-175 fusion
The fusion partners TENM4 and PPP6R3 have not been
seen in NRG1 fusions in tissue samples, but this is not
surprising, because there are already upwards of 30
known fusion partners (e.g. [9]). TENM4, teneurin4, has
been identified as a probable driver target of structural
variation, notably in the breast [37] and Fig. 3b of ref.
[39], and its relative TENM1/ODZ1 was identified as an
oncogene target of the mouse mammary tumour virus
(MMTV) [40]. It is a transmembrane protein with a
cytoplasmic N-terminus and a large extracellular do-
main, most of which is lost in the fusion (Fig. 3).
An important feature of the PPPR3-TENM4-NRG1 fu-
sion is that, paralleling wild-type NRG1, we found mul-
tiple isoforms, including isoforms with the cytoplasmic
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tail (Fig. 1). The original cDNA cloned by Schaefer et al.
[11] lacked the cytoplasmic domain of NRG1, and it has
often been assumed that this was a feature of NRG1 fu-
sions in general. The isoforms we found (Fig. 1) all had
the Ig-like domain, and they included both alpha and
beta forms (alternative exons 10 and 11). Some had the
full transmembrane and cytoplasmic C terminus desig-
nated 1a and 2a forms [1] while others, including the
original cDNA of Schaefer et al. [11], terminated in an
extended exon 11, designated -β3.
Alternative splicing of other NRG1 fusions
Many fusions have been presented as lacking the C-
terminal, cytoplasmic exons, and terminating in the β3,
non-transmembrane terminus (genomic exon 11ext).
But the multiple splice forms in MDA-MB-175 suggests
that these other fusions will also come in multiple iso-
forms, including forms with the cytoplasmic tail. Their
absence from the literature is probably an oversight:
partly a legacy of the original reports [4, 11] and partly
technical, because short-read sequencing only shows the
fusion junction, not downstream splicing patterns, and
PCR or single-primer amplification of cDNA has often
used primers in the β3 terminus (extended exon 11) or
the EGF-like domain (exon 9) (e.g. [5, 9]).
Further confusion arises because some NRG1 fusions
have been described as derivatives of NRG1 TypeIII-β3,
but this is misleading: no fusions involve the transcrip-
tion start site, genomic exon 7, that defines TypeIII
neuregulins/heregulins, and many of the fusions include
the Ig domains which are not in TypeIII-β3 [1].
It has also been assumed that the form of NRG1 se-
creted into the medium by MDA-MB-175 is encoded by
the original cDNA of Schaefer et al. [11], but this may
not be correct—it might be a cleaved fragment of a
transmembrane isoform (Fig. 3).
Oncogenic function of NRG1 fusions is paradoxical
The oncogenic function of NRG1 fusions is paradoxical
and remains to be fully explained. The fusions appar-
ently form an autocrine loop, stimulating the co-
expressed ERBB-ERBB2/HER2 heterodimer [12, 13]. But
normal epithelia produce both NRG1 and its receptors
[31, 41], so why would NRG1 fusions be oncogenic? And
NRG1 expression is pro-apoptotic when cDNAs are
transfected into cells, including the breast cancer cell
line MCF7 [42].
A possible resolution of this puzzle would be that
NRG1 and its ERBB-family receptors are, in normal epi-
thelium, produced by different cells, and/or on different
faces of the cell [41], with co-expression in the same cell
prevented by strong controls—perhaps leading to the
apoptotic activity of transfected NRG1 [42].
So why are NRG1 fusions oncogenic? One previous
hypothesis was that the cytoplasmic domain of NRG1 is
pro-apoptotic and is absent from the PPP6R3-TENM4-
NRG1 fusion [21]; our analysis rules this out.
We suggest two alternative explanations: alteration of
expression or alteration of subcellular localisation. Sim-
plest would be altered regulation of NRG1 expression, by
placing it downstream of an unrelated promoter, allowing
one cell to express ligand and receptor. This would be
consistent with the wide range of fusion partners.
Loss of nuclear signalling?
A more intriguing hypothesis is that the fusion proteins
have a different subcellular distribution, and, specifically,
that one route of nuclear signalling is lost.
NRG1 encodes many isoforms and proteolytically
cleaved forms, secreted, membrane-bound, cytoplasmic,
and nuclear [1, 43]. Among these, two entirely unrelated
forms can signal to the nucleus: the cleaved cytoplasmic
tail and the Type1-β3 form which includes the Ig-like
and EGF-like domains (Fig. 3). The latter is intracellular
because it lacks a transmembrane domain or signal se-
quence [2, 43], and it has been shown to translocate to
the nucleus and alter gene expression [44, 45]. Trans-
location is mediated by sequences around the Ig-like do-
main [44, 46] (Breuleux et al. [46] used a truncated
‘heregulin-alpha’ cDNA that lacked a transmembrane
domain).
The PPP6R3-TENM4-NRG1 fusion proteins consist of
the intracellular part of TENM4 and its transmembrane
domain, joined to a range of essentially intact NRG1 iso-
forms: the only exons of NRG1 lost are the first two
transcription-start exons (Fig. 3). Thus, TENM4 brings a
transmembrane domain to the fusion, and the TypeI-β3
forms that would normally be intracellular presumably
become extracellular (Fig. 3). Similarly, as noted by
others (e.g. [5]), several fusion partners bring a trans-
membrane domain, including two of the commonest,
CD74 and SLC3A2. Other fusion partners have a signal
sequence, e.g. SDC4 [5], CLU [8], ADAM9 [9], or fuse
with loss of the Ig-like domain, e.g. some CD74 fusions,
(See figure on previous page.)
Fig. 3 Predicted domain structure of the proteins encoded by the PPP6R3-TENM4-NRG1 fusion. Schematic diagrams showing the major domains
detected by SMART [38]. a Normal structures: a typical transmembrane NRG1 and a β3 isoform, and TENM4 (PPP6R3 contributes only untranslated
sequence). At least some β3 isoforms go to the nucleus [1, 43]. b Predicted structure of fusion proteins. One EGF-repeat and the transmembrane
domain of TENM4 are retained, juxtaposed to the Ig-like domain of NRG1. The chimeric protein may either include the transmembrane and
cytoplasmic region of NRG1 or the short β3 terminus
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RBPMS, TSHZ2 [9], again denying β3 forms access to
the nucleus. However, this is not a universal feature of
the fusions, e.g. the FOXA1 and ROCK1 fusions [8].
NRG1 can be a tumour suppressor or oncogene
Although NRG1 appears to be oncogenic in some tu-
mours, it is inactivated in carcinomas at least as often as
it is activated. NRG1 is silenced by methylation in some
breast and other carcinomas [31, 47, 48] and seems to
be at least one target of distal 8p loss, which is one of
the most frequent large-scale events in carcinomas [49].
Many of the rearrangements in NRG1 appear not to fuse
the gene or create a fusion that lacks the EGF-like,
receptor-binding domain, or are simply out of frame. Ex-
amples include a deletion in a breast cancer that
removes the ligand-binding domain [50] and three fur-
ther inactivating deletions [51]: fusions that retain only
the 5′ end of NRG1, e.g. two described by Drilon et al.
[8], and 3′ fusions that splice in at the transmembrane
domain [51]. Of 16 NRG1 fusions found in TCGA RNA-
seq data by Hu et al. [52], only 6 appeared to be in-
frame fusions of 3′ NRG1 that included the EGF-like
domain: four retained only the 5′ end, and most of the
others appeared out-of-frame. Many of the rearrange-
ments of NRG1 that we found in breast cancers did not
or were unlikely to create an activating fusion (Supple-
mentary Table 4), including the two fusions that were
out of frame.
This dual role could be because high ERBB3 activity
can be achieved in two ways: either NRG1 is inactivated
to permit high ERBB3 activity in all cells or at both faces
or to prevent NRG1’s pro-apoptotic activity [42] (which
may be a manifestation of the same control) or NRG1
can form an oncogenic autocrine loop, if control pre-
venting co-expression can be broken. The lack of nu-
clear signalling by the Ig-like domain might be part of
the control mechanism.
Whether or not this is the explanation, because many
NRG1 rearrangements seem to be inactivating, the cor-
rect identification of activating fusions may require care.
Conclusions
We show here firstly that the NRG1 fusion of the breast
cancer cell line MDA-MB-175, which serves as a model
NRG1 fusion, is more complex than previously reported.
It is a double fusion PPP6R3-TENM4-NRG1; is the result
of a complex genomic rearrangement; and, like normal
NRG1, is transcribed into multiple isoforms with differ-
ent subcellular locations. This sheds new light on the
mechanism of action of NRG1 fusions. Secondly, we
confirm that around 0.5% of breast cancers have NRG1
fusions of this activating type, but many more cases have
rearrangements of the NRG1 gene that seem more likely
to inactivate the gene or, as in MDA-MB-175, are too
complex to interpret from DNA sequence alone. NRG1
rearrangements will therefore require careful analysis
and interpretation for appropriate patient management.
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